SEC Form 4 · accession 0001562180-16-001766

Ultragenyx Pharmaceutical Inc. · RARE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due upon vesting of Restricted Stock Units granted to the Reporting Person under the Issuers 2014 Incentive Plan. The shares surrendered were valued based on the closing price of the Issuers common stock on the vesting date.
• F2Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
• F3This amount reflects a corrected balance due to clerical error. The number of shares as beneficially owned reported in December 2015 and January 2016 were 498 shares too high. The Form 4 filed on December 22, 2015 should have reported 13,231 shares as beneficially owned instead of 13,729 shares; the Form 4 filed on December 24, 2015 should have reported 12,733 shares as beneficially owned instead of 13,231 shares; and the Form 4 filed on January 21, 2016 should have reported 11,692 shares as beneficially owned instead of 12,190 shares.
• F4The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
• F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 to $63.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.